Non-coding RNA-based regulation of inflammation

Ashrafizadeh, Milad; Zarrabi, Ali; Mostafavi, Ebrahim; Aref, Amir Reza; Sethi, Gautam; Wang, Lingzhi; Tergaonkar, Vinay

doi:10.1016/j.smim.2022.101606

Cited by 61 publications

(26 citation statements)

References 392 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LncRNAs are involved in multiple physiological and pathological processes, the underlying mechanisms remain largely unknown [28][29][30]. In this study, data showed that ELFN1-AS1 was signi cantly upregulated in CRC tissues and promoted immune escape of CRC cells from NK cells.…”

Section: Discussionmentioning

confidence: 81%

ELFN1-AS1 Promotes GDF15-Mediated Immune Escape of Colorectal Cancer from NK cells by Facilitating GCN5 and SND1 Association

Han

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

The ability of colorectal cancer (CRC) cells to escape from natural killer (NK) cell immune surveillance leads to anti-tumor treatment failure. The long non-coding RNA (lncRNA) ELFN1-AS1 is aberrantly expressed in multiple tumors suggesting a role as an oncogene in cancer development. However, whether ELFN1-AS1 regulates immune surveillance in CRC is unclear. Here, we determined that ELFN1-AS1 enhanced the ability of CRC cells to escape from NK cell surveillance in vitro and in vivo. In addition, we confirmed that ELFN1-AS1 in CRC cells attenuated the activity of NK cell by down-regulating NKG2D and GZMB via the GDF15/JNK pathway. Furthermore, mechanistic investigations demonstrated that ELFN1-AS1 enhanced the interaction between the GCN5 and SND1 protein and this influenced H3k9ac enrichment at the GDF15 promotor to stimulate GDF15 production in CRC cells. Taken together, our findings indicate that ELFN1-AS1 in CRC cells suppresses NK cell cytotoxicity and ELFN1-AS1 is a potential therapeutic target for CRC.

show abstract

Section: Discussionmentioning

confidence: 81%

ELFN1-AS1 Promotes GDF15-Mediated Immune Escape of Colorectal Cancer from NK cells by Facilitating GCN5 and SND1 Association

Han

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Thus, regulating the m 6 A-modification status in circRNAs may control the target gene expression of circRNAs and the cellular biological functions ( 33 ). CircRNAs mainly affect miRNAs and reduce their expression in regulating cytokine levels ( 34 ). Cancer is one of the leading causes of death worldwide, and the factors responsible for its progression need to be elucidated ( 35 ).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of m6A-modified circRNAs in peritoneal metastasis of high grade serious carcinoma of ovary

Guo

Xu²,

Qiu³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

PurposeHigh-grade serous ovarian cancer (HGSOC) remains the most lethal female cancer due to metastasis. CircRNAs are recently identified to be modified by N6-methyladenosine (m6A) in many cells. However, the significance of m6A-modified circular RNAs (circRNAs) has not been elucidated in HGSOC peritoneal metastasis. Here, we aimed to investigate the participation and potential functions of m6A-modified circRNAs in HGSCO peritoneal metastasis.MethodsCancerous tissues were collected from the in situ and the peritoneal metastasis lesions of HGSCO patients. M6A-tagged circRNAs were identified by m6A-modified RNA immunoprecipitation sequencing (m6A-RIP-seq). Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to predict the potential functions of the m6A-modified circRNAs.ResultsFor the m6A-modified circRNAs, 259 were upregulated and 227 were downregulated in the peritoneal metastasis than in the situ lesions of HGSCO patients. For the m6A peaks, 1541 were upregulated and 1293 were downregulated in the peritoneal metastasis than in the in situ lesions of HGSCO patients. For the differential expressed circRNAs, 1911(19.6%) were upregulated and 2883(29.6%) were downregulated in the peritoneal metastasis than in the in situ lesions of HGSCO patients. The upregulated m6A-modified circRNAs were associated with the HIF-1 signaling. The downregulated m6A-modified circRNAs were associated with the MAPK signaling.ConclusionsThis work firstly identified the transcriptome-wide map of m6A-modified circRNAs in peritoneal metastasis of HGSCO. Our findings provided novel evidences about the participation of m6A-modified circRNAs via HIF-1 and MAPK signaling and a new insight in molecular target of HGSCO peritoneal metastasis.

show abstract

“…Cancer growth, progression, and chemotherapy treatment can all induce inflammation in cancer patients [ 174 , 175 , 176 , 177 , 178 ]. Therefore, as compared to synthetic drugs and formulations, natural bioactive metabolites that target different kinds of cancer may substantially alleviate side effects and offer new alternatives to the standard of care for cancer patients [ 179 , 180 , 181 , 182 ]. Currently, only a few bioactive compounds isolated from various natural sources have been tested clinically for cancer treatment, and one of these bioactive compounds, withaferin A, isolated from W. somnifera , has potential anticancer, anti-inflammatory, and antioxidant properties [ 183 , 184 , 185 ].…”

Section: Anti-inflammatory and Antioxidant Activities Of Withaferin Amentioning

confidence: 99%

Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal

Kumar

Mathew

Aharwal³

et al. 2023

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

Cancer represents the second most deadly disease and one of the most important public health concerns worldwide. Surgery, chemotherapy, radiation therapy, and immune therapy are the major types of treatment strategies that have been implemented in cancer treatment. Unfortunately, these treatment options suffer from major limitations, such as drug-resistance and adverse effects, which may eventually result in disease recurrence. Many phytochemicals have been investigated for their antitumor efficacy in preclinical models and clinical studies to discover newer therapeutic agents with fewer adverse effects. Withaferin A, a natural bioactive molecule isolated from the Indian medicinal plant Withania somnifera (L.) Dunal, has been reported to impart anticancer activities against various cancer cell lines and preclinical cancer models by modulating the expression and activity of different oncogenic proteins. In this article, we have comprehensively discussed the biosynthesis of withaferin A as well as its antineoplastic activities and mode-of-action in in vitro and in vivo settings. We have also reviewed the effect of withaferin A on the expression of miRNAs, its combinational effect with other cytotoxic agents, withaferin A-based formulations, safety and toxicity profiles, and its clinical potential.

show abstract

Non-coding RNA-based regulation of inflammation

Cited by 61 publications

References 392 publications

ELFN1-AS1 Promotes GDF15-Mediated Immune Escape of Colorectal Cancer from NK cells by Facilitating GCN5 and SND1 Association

ELFN1-AS1 Promotes GDF15-Mediated Immune Escape of Colorectal Cancer from NK cells by Facilitating GCN5 and SND1 Association

Comprehensive analysis of m6A-modified circRNAs in peritoneal metastasis of high grade serious carcinoma of ovary

Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal

Contact Info

Product

Resources

About